GSK announces first global Phase Ib EMBOLD PanTumour-101 data for Ris-Rez in relapsed ES-SCLC

GSK announced first global Phase Ib EMBOLD PanTumour-101 data showing anti-tumour activity and a manageable safety profile for Ris-Rez in relapsed extensive-stage small-cell lung cancer (ES-SCLC).

Detected & updated continuously · Source: Nebula